Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class, non-opioid, treatments for chronic and acute ...
In exchange, the Company has agreed to issue to Conjoint 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share ... includes IMC-1 and IMC-2, which ...
In exchange, the Company has agreed to issue to Conjoint 284.2638 shares of Series A-1 Non-Voting Convertible Preferred Stock, par value $0.0001 per share ... includes IMC-1 and IMC-2, which ...
Dogwood’s antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed-dose combinations of anti-herpes antivirals and the anti-inflammatory agent celecoxib. These combination ...
One of the most exciting developments in Immunocore’s pipeline is IMC-M113V, a potential treatment for HIV. Recent Phase 1 data presented at the Conference on Retroviruses and Opportunistic Infections ...
The S&P/ASX 200 index fell 1.2% to 7,793.6, as of 0001 GMT. The benchmark fell as much as 1.6% earlier in the session, down about 10% from its all-time high touched on February 14, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback